Standard Nuclear Q3 2026: Backlog Doubles, Loss Widens on IPO Costs

Standard Nuclear's first earnings report as a public company showed revenue of $5.96 million, clearing the $5.54 million consensus by about 7.6%. That growth reflects a surge in commercial TRISO fuel deliveries, which generated $3.7 million in product revenue, alongside $2.2 million from development services and government projects.

The contracted backlog more than doubled to $577.2 million from $241.5 million at June 30, anchored by an August fuel supply agreement with Antares Nuclear covering firm and optional HALEU TRISO commitments of up to eight MTU in total. That figure is a meaningful signal for a company still in its early production ramp.

The loss per share of $0.10 came in well short of expectations against an analyst estimate of $0.04, but the gap is largely a bookkeeping artifact of going public. The quarter absorbed $10.3 million in share-based compensation, including $9.5 million in general and administrative expense tied to IPO-related awards. CEO Kurt Terrani noted the company delivered its first reactor core and submitted the final Documented Safety Analysis for its Tennessee facility during the quarter.

Standard Nuclear is targeting DOE authorization to operate both its Tennessee and Idaho plants by February 28, 2027. Those two facilities, construction of which is substantially complete, have a combined potential capacity of up to five MTU of HALEU TRISO fuel per year. A Framatome joint venture is separately planning to begin TRISO production at its Richland facility in 2027 at an initial capacity of roughly one MTU annually.

The balance sheet entering this phase looks stable. The company held $223.1 million in cash at quarter end against total liabilities of only $14.2 million, a cushion built largely from IPO proceeds. Interest income of $2.0 million on those proceeds partially offset operating losses during the quarter.

The key variable from here is regulatory timing. DOE authorization for both facilities is the prerequisite for full commercial HALEU production, and any slip beyond the February 2027 target would push out the revenue ramp that the growing backlog implies. Share-based compensation will also continue to weigh on GAAP results over the remaining vesting periods of the IPO-related awards.